Dysbiosis in the Gut Microbiome of Pembrolizumab‐Treated Non‐Small Lung Cancer Patients Compared to Healthy Controls Characterized Through Opportunistic Sampling
Thoracic Cancer · 2025-05 · 16 (9)
DOI: 10.1111/1759-7714.70075 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Thoracic Cancer, online erschienen am 12.05.2025. Verfasst von Haris Charalambous und 13 weiteren Autor:innen. Beteiligte Einrichtung: Bank of Cyprus Oncology Centre, Nicosia, Cyprus. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Carcinoma, Non-Small-Cell Lung, Dysbiosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The gut microbiome influences the host immune system, cancer development and progression, as well as the response to immunotherapy during cancer treatment. Here, we analyse the composition of the gut bacteriome in metastatic Non‐Small Cell Lung Cancer (NSCLC) patients receiving Pembrolizumab immunotherapy within a prospective maintenance trial through opportunistic sampling during treatment.
Methods
The gut microbiome profiles of NSCLC patients were obtained from stool samples collected during Pembrolizumab treatment and analysed with 16S rRNA metagenomics sequencing. Patient profiles were compared to a group of healthy individuals of matching ethnic group, age, sex, BMI and comorbidities.
Results
A significant decrease in the treated patients was observed in two prominent bacterial families of the phylum Firmicutes, Lachnospiraceae and Ruminoccocaceae, which comprised 31.6% and 21.8% of the bacteriome in the healthy group but only 10.9% and 14.2% in the treated patient group, respectively. Species within the Lachnospiraceae and Ruminococcaceae families are known to break down undigested carbohydrates generating short chain fatty acids (SCFA), such as butyrate, acetate and propionate as their major fermentation end‐products, which have been implicated in modifying host immune responses. In addition, a significant increase of the Bacteroidacaeae family (Bacteroidetes phylum) was observed from 10.7% in the healthy group to 23.3% in the treated patient group. Moreover, and in agreement with previous studies, a decrease in the Firmicutes to Bacteroidetes ratio in the metastatic NSCLC Pembrolizumab‐treated patients was observed.
Conclusion
The observed differences indicate dysbiosis and a compromised intestinal health status in the metastatic NSCLC Pembrolizumab‐treated patients. This data could inform future studies of immunotherapy treatment responses and modulation of the gut microbiome to minimise dysbiosis prior or concurrent to treatment. Trial Registration: SWIPE Trial (NCT 02705820).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bank of Cyprus Oncology Centre, Nicosia, Cyprus.
- Stremble Ventures Ltd, Limassol, Cyprus.
- European University Cyprus, Engomi, Cyprus.
- Department of Biological Sciences, University of Cyprus, Nicosia, Cyprus.
- Avva Pharmaceuticals Ltd, Limassol, Cyprus.
- Karaiskakio Foundation, Nicosia, Cyprus.
ORCID-Profile: Athos Antoniades
Förderung
- Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp
Zitieren
APA
Charalambous, H., Brown, C., Vogazianos, P., Katsaounou, K., Nikolaou, E., Stylianou, I., Papageorgiou, E., Vraxnos, D., Aristodimou, A., Chi, J., Costeas, P., Shammas, C., Apidianakis, Y., & Antoniades, A. (2025). Dysbiosis in the Gut Microbiome of Pembrolizumab‐Treated Non‐Small Lung Cancer Patients Compared to Healthy Controls Characterized Through Opportunistic Sampling. Thoracic Cancer, 16(9). https://doi.org/10.1111/1759-7714.70075
Vancouver
Charalambous H, Brown C, Vogazianos P, Katsaounou K, Nikolaou E, Stylianou I, et al. Dysbiosis in the Gut Microbiome of Pembrolizumab‐Treated Non‐Small Lung Cancer Patients Compared to Healthy Controls Characterized Through Opportunistic Sampling. Thoracic Cancer. 2025;16(9). doi:10.1111/1759-7714.70075
BibTeX
@article{Charalambous2025,
author = {Charalambous, Haris and Brown, Cameron and Vogazianos, Paris and Katsaounou, Kyriaki and Nikolaou, Elpiniki and Stylianou, Ioannis and Papageorgiou, Elisavet and Vraxnos, Dimitris and Aristodimou, Aristos and Chi, Jianxiang and Costeas, Paul and Shammas, Christos and Apidianakis, Yiorgos and Antoniades, Athos},
title = {Dysbiosis in the Gut Microbiome of Pembrolizumab‐Treated Non‐Small Lung Cancer Patients Compared to Healthy Controls Characterized Through Opportunistic Sampling},
journal = {Thoracic Cancer},
year = {2025},
volume = {16},
number = {9},
doi = {10.1111/1759-7714.70075}
}
EUVIMED